이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Senzime 관리

관리 기준 확인 3/4

Senzime's CEO는 Philip Siberg, May2023 에 임명되었습니다 의 임기는 1.08 년입니다. 총 연간 보상은 SEK 4.61M, 55.2% 로 구성됩니다. 55.2% 급여 및 44.8% 보너스(회사 주식 및 옵션 포함). 는 € 476.88K 가치에 해당하는 회사 주식의 0.59% 직접 소유합니다. 476.88K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 3.3 년입니다.

주요 정보

Philip Siberg

최고 경영자

SEK 4.6m

총 보상

CEO 급여 비율	55.2%
CEO 임기	1.1yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Philip Siberg 의 보수는 Senzime 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-SEK 131m
Dec 31 2023	SEK 5m	SEK 3m	-SEK 134m
Sep 30 2023	n/a	n/a	-SEK 138m
Jun 30 2023	n/a	n/a	-SEK 137m
Mar 31 2023	n/a	n/a	-SEK 143m
Dec 31 2022	SEK 450k	n/a	-SEK 133m
Sep 30 2022	n/a	n/a	-SEK 114m
Jun 30 2022	n/a	n/a	-SEK 104m
Mar 31 2022	n/a	n/a	-SEK 86m
Dec 31 2021	SEK 400k	n/a	-SEK 82m
Sep 30 2021	n/a	n/a	-SEK 74m
Jun 30 2021	n/a	n/a	-SEK 66m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 100k	n/a	-SEK 47m
Sep 30 2020	n/a	n/a	-SEK 41m
Jun 30 2020	n/a	n/a	-SEK 36m
Mar 31 2020	n/a	n/a	-SEK 32m
Dec 31 2019	SEK 100k	n/a	-SEK 33m
Sep 30 2019	n/a	n/a	-SEK 34m
Jun 30 2019	n/a	n/a	-SEK 33m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 100k	n/a	-SEK 24m
Sep 30 2018	n/a	n/a	-SEK 19m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 13m
Dec 31 2017	SEK 131k	n/a	-SEK 13m

보상 대 시장: Philip 의 총 보상 ($USD 442.11K )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 434.78K ).

보상과 수익: 회사가 수익성이 없는 동안 Philip 의 보상이 증가했습니다.

CEO

Philip Siberg (51 yo)

1.1yrs

테뉴어

SEK 4,614,088

보상

Mr. Philip Siberg serves as the Chief Executive Officer of Stille Surgical, Inc. He serves as Chairman of the Board at Acarix AB (publ) since May 11, 2021. He was Co-Founder of Coala-Life Group AB (publ) a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Philip Siberg	Chief Executive Officer	1.1yrs	SEK 4.61m	0.59% SEK 491.6k
Slavoljub Grujicic	Chief Financial Officer	2.4yrs	데이터 없음	0.021% SEK 17.4k
Johanna Tulkki	Chief Operating Officer	4.4yrs	데이터 없음	데이터 없음
Fredrik Norrby	Chief Technology Officer	1.4yrs	데이터 없음	데이터 없음
Rianne Waninge	Application Scientist	no data	데이터 없음	데이터 없음
Paula Treutiger	Head of Communication & Investor Relations	2.4yrs	데이터 없음	데이터 없음
Anders Selin	Executive Vice President of Sales	4.8yrs	데이터 없음	데이터 없음
Michael Noble	Vice President Global Marketing	less than a year	데이터 없음	데이터 없음
Anders Jacobson	Chief Innovation Officer	8.4yrs	데이터 없음	0.013% SEK 11.2k
Catrin Molund	Executive Vice President of Business Development	3.4yrs	SEK 163.00k	데이터 없음
Johanna Faris	Head of Q/RA/S	less than a year	데이터 없음	0.0013% SEK 1.1k

2.4yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: 6YC 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Per Wold-Olsen	Chairman of the Board	less than a year	데이터 없음	0.34% SEK 285.7k
Goran Brorsson	Independent Director	1.1yrs	SEK 131.00k	0.085% SEK 70.7k
Adam Dahlberg	Vice Chairman of the Board	24.4yrs	SEK 350.00k	5.25% SEK 4.4m
Eva Walde	Independent Director	3.3yrs	SEK 210.00k	데이터 없음
Sorin Brull	Member of Clinical Advisory Board	8.4yrs	SEK 1.31m	3.15% SEK 2.6m
Alfredo Abad-Gurumeta	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Bela Fulesdi	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Guy Cammu	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Hans Boer	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Claude Meistelman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jennifer Hunter	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Casper Claudius	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: 6YC 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.

Senzime 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

Less than half of directors are independent

Independent Chairman recently bought €66k worth of stock

Recent updates

Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System

New minor risk - Profitability

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.74 loss in 3Q 2022)

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

No longer forecast to breakeven

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

No longer forecast to breakeven

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Less than half of directors are independent

Independent Chairman recently bought €66k worth of stock

Less than half of directors are independent

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Less than half of directors are independent

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Senzime AB (publ) Provides Earnings Guidance for 2025

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Less than half of directors are independent

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings released: kr0.33 loss per share (vs kr0.27 loss in 1Q 2021)

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령